Abstract
Table S1. ETS genes with weaker evidence for association with ERG fusion status. Table S2. Androgen receptor transcriptional activity, measured as a más-o-menos score of the Hiernonymus et al. (2006) signature and expressed in standard deviations within a cohort, between ETS-defined subtypes, in TCGA and the Hopkins cohort. Table S3. All genes associated with ERG vs. non-ERG status among the Berglund et al. ETS genes, sorted by increasing p-value in HPFS/PHS. Missing estimates for the validation cohorts (HPFS/PHS and Hopkins) indicate the gene was not measured on the microarrays used in these studies. Table S4. Ratios between Black and White men for ratios of expression between ETS vs. non-ETS tumors. Table S5. Gene set analysis for Hallmark gene sets associated with ERG vs. non-ERG (top), ETS vs. non-ETS (middle), and non-ERG ETS vs. non-ETS status (bottom). Figure S1. Gene expression ratios in TCGA for ETS vs. non-SPOP non-ETS (x axis) and ETS vs. SPOP non-ETS (y-axis). One dot is one tumor. Figure S2. Androgen receptor transcriptional activity by subtype. One dot is one tumor. Figure S3. ETS-related AR target genes.